ASHM Testing Portal
The Testing Policies offered by ASHM are specifically designed for healthcare professionals and pathologists who order or conduct HIV, hepatitis C, and hepatitis B tests, as well as those involved in interpreting and delivering the test results to patients. These policies establish a comprehensive framework that ensures high-quality testing while eliminating both real and perceived […]
Communicare User Manual: Viral Hepatitis
This manual was developed in collaboration with the Aboriginal Health Council of South Australia (AHCSA), and provides a comprehensive guide for best practice screening, testing and management of viral hepatitis. It provides step by step details for implementation of best practice within Communicare, and aims to standardise viral hepatitis management across ACCHSs nationally. For a […]
REACH-C
All General Practitioners, other Primary Care Physicians and Authorised Nurse Practitioners in Australia can prescribe medication for hepatitis C. Practitioners who are not experienced in hepatitis C treatment are required to consult with an experienced specialist before initiating HCV therapy. The online Reach-C Form provides a time effective option to receive specialist approval within 24 hours.
New call for change in legislation for hepatitis C treatment in hospitals
A new evidence summary by Burnet Institute has revealed some people with hepatitis C in hospitals are not accessing treatment due to the cost of medication, sparking calls for the federal government to review legislation to improve access. Published jointly by Burnet Institute, Hepatitis Australia and ASHM, the summary suggests that preventing people in hospital […]
Hepatitis C treatment access for hospital inpatients
Since March 2016, direct acting antivirals (DAAs) to cure hepatitis C have been available under the Pharmaceutical Benefits Scheme (PBS) in the community and in outpatient settings, via the General Schedule (s85) or the Highly Specialised Drugs Program (s100). However, existing regulation prevents those in hospital inpatient settings from accessing PBS subsidies for DAAs. Inpatient […]
Curing Hepatitis C in Primary Care
“>”>Curing Hepatitis C in Primary Care Treatment with direct acting antivirals is easier than ever – join our interactive course on hepatitis C (HCV) management in primary care! Last Updated: 1/10/24 Increasing HCV treatment in primary care is crucial to achieving HCV elimination in Australia by 2030. This course aims to empower general practitioners, nurse […]
Combating hepatitis C in primary care
Hepatitis C virus (HCV) kills approximately 483 people in Australia each year – despite being curable in primary care. That means every death from HCV is avoidable and the elimination of hepatitis C in Australia is a very real possibility. But to get there, there is still plenty of work to do. Hepatitis C is […]
Remote prescribing breaking down barriers to hepatitis C treatment in New South Wales
Hepatitis C is curable in most people. Hepatitis C treatment in the form of direct-acting antiviral medicines (DAAs) can cure more than 95% of people living with hepatitis C. While the number of people living with hepatitis C is decreasing overall, the cumulative proportion of people living with hepatitis C initiating DAA treatment remains lower […]
Stigma and discrimination, no place in healthcare.
Stigma and discrimination, no place in healthcare. These resources serve as a guide and support for healthcare professionals seeking to understand and address the impact of stigma and discrimination on patient care. Our materials cover best practices for creating inclusive healthcare environments, identification and mitigation of bias, and relevant research and literature on the topic. […]
NSW Hepatitis C Remote Prescribing Program
The NSW Hepatitis C Remote Prescribing Program was established in November 2020 to facilitate linkages between nurses who perform the patient assessment and medical practitioners/nurse practitioners who initiate hepatitis C treatment. The program aims to increase access to hepatitis C treatment in NSW in regional areas and other settings where treatment may be limited. Further […]
